Ontology highlight
ABSTRACT:
SUBMITTER: Hernandez C
PROVIDER: S-EPMC7177687 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
Hernandez Carlos C Arasanz Hugo H Chocarro Luisa L Bocanegra Ana A Zuazo Miren M Fernandez-Hinojal Gonzalo G Blanco Ester E Vera Ruth R Escors David D Kochan Grazyna G
International journal of molecular sciences 20200331 7
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of I ...[more]